Mechanisms of neuronal death in Huntington's disease. Second part: Therapeutic challenges;Mécanismes de mort neuronale dans la maladie de Huntington. Seconde partie: Aspects thérapeutiques

Revue Medicale de Bruxelles

Volumn 28, Issue 6, 2007, Pages 487-494

  Bantubungi, K ^a,b   Blum, D ^a,b  

^a JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^b UNIV LILLE   (France)

Author keywords

Huntingtin; Huntington's disease; Neuronal death

Indexed keywords

ALPHA TOCOPHEROL; BUTYRIC ACID; CELECOXIB; CREATINE; CYSTAMINE; HISTONE DEACETYLASE INHIBITOR; IDEBENONE; MERCAPTAMINE; MINOCYCLINE; MITHRAMYCIN; RAPAMYCIN; REMACEMIDE; RESVERATROL; RILUZOLE; TREHALOSE; UBIQUINONE; VORINOSTAT;

BRAIN CORTEX; BRAIN DEGENERATION; CELL THERAPY; COGNITIVE DEFECT; CORPUS STRIATUM; GENE MUTATION; HUMAN; HUNTINGTON CHOREA; MOTOR DYSFUNCTION; NERVE CELL NECROSIS; NONHUMAN; PATHOPHYSIOLOGY; REVIEW;

CELL DEATH; GENE THERAPY; HUMANS; HUNTINGTON DISEASE; NERVE DEGENERATION; NEURONS; TRANSCRIPTION, GENETIC;

EID: 37649009901     PISSN: 00353639     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (222)

1. Huntington G : On Chorea, Medical and Surgical Reporter of Philadelphia, 1872
2. Bates G : Huntington's disease. Oxford University Press, Oxford, 2002
3. Kremer B, Weber B, Hayden MR : New insights into the clinical features, pathogenesis and molecular genetics of Huntington disease. Brain Pathol 1992 ; 2 : 321-35
4. Lawrence AD, Sahakian BJ, Hodges JR, Rosser AE, Lange KW, Robbins TW : Executive and mnemonic functions in early Huntington's disease. Brain 1996 ; 119 : 1633-45
5. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr : Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol : 1985 ; 44 : 559-77
6. Ferrante RJ, Kowall NW, Beal MF, Richardson EP Jr, Bird ED, Martin JB : Selective sparing of a class of striatal neurons in Huntington's disease. Science 1985 ; 230 : 561-3
7. Ferrante RJ, Beal MF, Kowall NW, Richardson EP Jr, Martin JB : Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease. Brain Res 1987 ; 411 : 162-6
8. Ferrante RJ, Kowall NW, Beal MF, Martin JB, Bird ED, Richardson EP Jr : Morphologic and histochemical characteristics of a spared subset of striatal neurons in Huntington's disease. J Neuropathol Exp Neurol 1987 ; 46 : 12-27
9. Mitchell IJ, Cooper AJ, Griffiths MR : The selective vulnerability of striatopallidal neurons. Prog Neurobiol 1999 ; 59 : 691-719
10. Fennema-Notestine C, Archibald SL, Jacobson MW et al. : In vivo evidence of cerebellar atrophy and cerebral white matter loss in Huntington disease. Neurology 2004 ; 63 : 989-95
11. Kassubek J, Gaus W, Landwehrmeyer GB : Evidence for more widespread cerebral pathology in early HD : an MRI-based morphometry analysis. Neurology 2004 ; 62 : 523-4
12. Petersen A, Bjorkqvist M : Hypothalamic-endocrine aspects in Huntington's disease. Eur J Neurosci 2006 ; 24 : 961-7
13. Sapp E, Kegel KB, Aronin N et al. : Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol 2001 ; 60 : 161-72
14. The Huntington's disease collaborative research group : A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993 ; 72 : 971-83
15. Everett CM, Wood NW : Trinucleotide repeats and neurodegenerative disease. Brain 2004 ; 127 : 2385-405
16. McDonald ME, Gines S, Gusella JF, Wheeler VC : Huntington's disease. Neuromolecular Med 2003 ; 4 : 7-20
17. Gusella JF, McDonald ME : Molecular genetics : unmasking polyglutamine triggers in neurodegenerative disease. Nat Rev Neurosci 2000 ; 1 : 109-15
18. Penney JB Jr, Vonsattel JP, MacDonald ME, Gusella JF, Myers RH : CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol 1997 ; 41: 689-92
19. Snell RG, MacMillan JC, Cheadle JP et al. : Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat Genet 1993 ; 4 : 393-97
20. Wexler NS, Lorimer J, Porter J et al. : Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc Natl Acad Sci U S A 2004 ; 101 : 3498-503
21. Anca MH, Gazit E, Loewenthal R, Ostrovsky O, Frydman M, Giladi N : Different phenotypic expression in monozygotic twins with Huntington disease. Am J Med Genet A 2004 ; 124 : 89-91
22. Friedman JH, Trieschmann ME, Myers RH, Fernandez HH : Monozygotic twins discordant for Huntington disease after 7 years. Arch Neurol 2005 ; 62 : 995-7
23. Arning L, Kraus PH, Valentin S, Saft C, Andrich J, Epplen JT : NR2A and NR2B receptor gene variations modify age at onset in Huntington disease. Neurogenetics 2005 ; 6 : 25-8
24. MacDonald ME, Vonsattel JP, Shrinidhi J et al. : Evidence for the GluR6 gene associated with younger onset age of Huntington's disease. Neurology 199 ; 53 : 1330-2
25. Alberch J, Lopez M, Badenas C et al. : Association between BDNF Val66Met polymorphism and age at onset in Huntington disease. Neurology 2005 : 964-6
26. Di Maria E, Marasco A, Tartari M et al. : No evidence of association between BDNF gene variants and age-at-onset of Huntington's disease. Neurobiol Dis 2006 ; 24 : 274-9
27. Kishikawa S, Li JL, Gillis T et al. : Brain-derived neurotrophic factor does not influence age at neurologic onset of Huntington's disease. Neurobiol Dis 2006 ; 24 : 280-5
28. Chattopadhyay B, Ghosh S, Gangopadhyay PK et al. : Modulation of age at onset in Huntington's disease and spinocerebellar ataxia type 2 patients originated from eastern India. Neurosci Lett 2003 ; 345 : 93-6
29. Metzger S, Bauer R Tomiuk J et al. : The S18Y polymorphism in the UCHL1 gene is a genetic modifier in Huntington's disease. Neurogenetics 2006 : 27-30
30. Chattopadhyay B, Baksi K, Mukhopadhyay S, Bhattacharyya NP : Modulation of age at onset of Huntington disease patients by variations in TP53 and human caspase activated DNase (hCAD) genes. Neurosci Lett 2005 ; 374 : 81-6
31. Trottier Y, Devys D, Imbert G et al. : Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. Nat Genet 1995 ; 10 : 104-10
32. Ferrante RJ, Gutekunst CA, Persichetti F et al. : Heterogeneous topographic and cellular distribution of huntingtin expression in the normal human neostriatum. J Neurosci 1997 ; 17 : 3052-63
33. Gourfinkel-An I, Cancel G, Trottier Y et al. : Differential distribution of the normal and mutated forms of huntingtin in the human brain. Ann Neurol 1997 ; 42 : 712-9
34. Aronin N, Chase K, Young C et al. : CAG expansion affects the expression of mutant Huntingtin in the Huntington's disease brain. Neuron 1995 ; 15 : 1193-201
35. Landwehrmeyer GB, McNeil SM, Dure LS et al. : Huntington's disease gene : regional and cellular expression in brain of normal and affected individuals. Ann Neurol 1995 ; 37 : 218-30
36. Harjes P, Wanker EE : The hunt for huntingtin function : interaction partners tell many different stories. Trends Biochem Sci 2003 ; 28 : 425-33
37. Sun Y, Savanenin A, Reddy PH, Liu YF : Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95. J Biol Chem 2001 ; 276 : 24713-8
38. Gauthier LR, Charrin BC, Borrell-Pages M et al. : Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 2004 ; 118 : 127-38
39. Rigamonti D, Bauer JH, De Fraja C et al. : Wild-type huntingtin protects from apoptosis upstream of caspase-3. J Neurosci 2000 ; 20 : 3705-13
40. Rigamonti D, Sipione S, Goffredo D, Zuccato C, Fossale E, Cattaneo E : Huntingtin's neuroprotective activity occurs via inhibition of procaspase-9 processing. J Biol Chem 2001 ; 276 : 14545-8
41. Zhang Y, Leavitt BR, van Raamsdonk JM et al. : Huntingtin inhibits caspase-3 activation. EMBO J 2006 ; sous presse
42. Duyao MP, Auerbach AB, Ryan A et al. : Inactivation of the mouse Huntington's disease gene homolog Hdh. Science 1995 ; 269 : 407-10
43. Nasir J, Floresco SB, O'Kusky JR et al. : Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 1995 ; 81 : 811-23
44. Zeitlin S, Liu JP, Chapman DL, Papaioannou VE, Efstratiadis A : Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat Genet 1995 ; 11 : 155-63
45. Dragatsis I, Levine MS, Zeitlin S : Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat Genet 2000 ; 26 : 300-6
46. Zuccato C, Ciammola A, Rigamonti D et al. : Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001 ; 293 : 493-8
47. Zuccato C, Tartari M, Crotti A et al. : Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet 2003 ; 35 : 76-83
48. Cattaneo E, Zuccato C, Tartari M : Normal huntingtin function : an alternative approach to Huntington's disease. Nat Rev Neurosci 2005 ; 6 : 919-30
49. Cattaneo E : Dysfunction of wild-type huntingtin in Huntington disease. News Physiol Sci 2003 ; 18 : 34-7
50. Van Raamsdonk JM, Murphy Z, Slow EJ, Leavitt BR, Hayden MR : Selective Degeneration and Nuclear Localization of Mutant Huntingtin in the YAC128 Mouse Model of Huntington Disease. Hum Mol Genet 2005 ; 14 : 3823-35
51. Li SH, Li XJ : Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet 2004 ; 3 : 146-54
52. Petersen A, Mani K, Brundin P : Recent advances on the pathogensis of Huntington's disease. Exp Neurol 1999 ; 157 : 1-18
53. Saudou F, Finkbeiner S, Devys D, Greenberg ME : Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 1998 ; 95 : 55-66
54. Lunkes A, Trottier Y, Mandel JL : Pathological mechanisms in Huntingtion's disease and other polyglutamine expansion diseases. Essays Biochem 1998 ; 33 : 149-63
55. DiFiglia M, Sapp E, Chase KO et al. : Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997 ; 277 : 1990-3
56. Sapp E, Penney J, Young A, Aronin N, Vonsattel JP, DiFiglia M : Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in Huntington disease. J Neuropathol Exp Neurol 1999 ; 58 : 165-73
57. Vonsattel JP, DiFiglia M : Huntington's disease. J Neuropathol Exp Neurol 1998 ; 57 : 369-84
58. Peruttz MF, Johnson T, Suzuki M, Fich JT : Glutamine repeats as polar zippers : their possible role in inherited neurodegenerative diseases. Proc Natl Acad Sci U S A 1994 ; 91 : 5355-8
59. Stott K, Blackburn JM, Butler PJG, Perutz M : Incorporation of glutamine repeats makes protein oligomerize : implications for neurodegenerative diseases. Proc Natl Acad Sci U S A 1995 ; 92 : 6509-13
60. Karpuj MV, Becher MW, Springer JE et al. : Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med 2002 ; 8 : 143-9
61. Wellington CL, Ellerby LM, Leavitt B, Roy S, Nicholson DW, Hayden MR : Huntingtin proteolysis in Huntington's disease. Clin Neurosci Res 2003 ; 3 : 129-39
62. Qin ZH, Wang J, Gu ZL : Development of novel therapies for Huntington's disease : hope and challenge. Acta Pharmacol Sin 2005 ; 26 : 129-42
63. Gutekunst CA, Li SH, Yi H et al. : Nuclear and neuropil aggregates in Huntington's disease : relationship to neuropathology. J Neurosci 1999 ; 19 : 2522-34
64. Graham RK, Deng Y, Slow EJ et al. : Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 2006 ; 125 : 1179-91
65. Ravikumar B, Vacher C, Berger Z et al. : Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 2004 ; 36 : 585-95
66. Schaffar G, Breuer P, Boteva R et al. : Cellular toxicity of polyglutamine expansion proteins : mechanism of transcription factor deactivation. Mol Cell 2004 ; 15 : 95-105
67. Kuemmerle S, Gutekunst CA, Klein AM et al. : Huntington aggregates may not predict neuronal death in Huntington's disease. Ann Neurol 1999 ; 46 : 842-9
68. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S : Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004 ; 431 : 805-10
69. Slow EJ, Graham RK, Osmand AP et al. : Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proc Natl Acad Sci U S A 2005 ; 102 : 11402-7
70. Augood SJ, Faull RL, Love DR, Emson PC : Reduction in enkephalin and substance P messenger RNA in the striatum of early grade Huntington's disease : a detailed cellular in situ hybridization study. Neuroscience 1996 ; 72 : 1023-36
71. Weeks RA, Piccini P, Harding AE, Brooks DJ : Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Ann Neurol 1996 ; 40 : 49-54
72. Augood SJ, Faull RL, Emson PC : Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease. Ann Neurol 1997 ; 42 : 215-21
73. Cha JH, Kosinski CM, Kerner JA et al. : Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. Proc Natl Acad Sci U S A 1998 ; 95 : 6480-5
74. Cha JH, Frey AS, Alsdorf SA et al. : Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Philos Trans R Soc Lond B Biol Sci 1999 ; 354 : 981-9
75. Bibb JA, Yan Z, Svenningsson P et al. : Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. Proc Natl Acad Sci U S A 2000 ; 97 : 6809-14
76. Denovan-Wright EM, Robertson HA : Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice. Neuroscience 2000 ; 98 : 705-13
77. Luthi-Carter R, Hanson SA, Strand AD et al. : Dysregulation of gene expression in the R6/2 model of polyglutamine disease : parallel changes in muscle and brain. Hum Mol Genet 2002 ; 11 : 1911-26
78. Spektor BS, Miller DW, Hollingsworth ZR et al. : differential D1 and D2 receptor-mediated effects on immediate early gene induction in a transgenic mouse model of Huntington's disease. Brain Res Mol Brain Res 2002 ; 102 : 118-28
79. Luthi-Carter R, Strand AD, Hanson SA et al. : Polyglutamine and transcription : gene expression changes shared by DRPLA and Huntington's disease mouse model reveal context-dependent independent-effects. Hum Mol Genet 2002 ; 11 : 1927-37
80. Luthi-Carter R, Cha JHJ : Mechanisms of transcriptional dysregulation in Huntington's disease. Clinical Neuroscience Research 2003 ; 3 : 165-77
81. Nucifora FC Jr, Sasaki M, Peters MF et al. : Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 2001 ; 291 : 2423-8
82. Jiang H, Nucifora FC Jr, Ross CA, DeFranco DB : Cell death triggered by polyglutamine-expanded huntingtin in a neuronal cell line is associated with degradation of CREB-binding protein. Hum Mol Genet 2003 ; 12 : 1-12
83. Steffan JS, Bodai L, Pallos J et al. : Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001 ; 413 : 739-43
84. Mantamadiotis T, Lemberger T, Bleckmann SC et al. : Disruption of CREB function in brain leads to neurodegeneration. Nat Genet 2002 ; 31 : 47-54
85. Zhai W, Jeong H, Cui L, Krainc D, Tjian R : In vitro analysis of huntingtin-mediated transcriptional repression reveals multiple transcription factor targets. Cell 2005 ; 123 : 1241-53
86. LaMonte BH, Wallace KE, Holloway BA et al. : Disruption of dynein/dynactin inhibits axonal transport in motor neurons causing late-onset progressive degeneration. Neuron 2002 ; 34 : 715-27
87. Crosby AH : Disruption of cellular transport : a common cause of neurodegeneration ? Lancet Neurol 2003 ; 2 : 311-6
88. Charrin BC, Saudou F, Humbert S : Axonal transport failure in neurodegenerative disorders : the case of Huntington's disease. Pathol Biol (Paris) 2005 ; 53 : 189-92
89. DiFiglia M, Sapp E, Chase K et al. : Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 1995 ; 14 : 1075-81
90. Block-Galarza J, Chase KO, Sapp E et al. : Fast transport and retrograde movement of huntingtin and HAP1 in axons. Neuroreport 1997 ; 8 : 2247-51
91. Gutekunst CA, Levey AI, Heilman CJ et al. : Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies. Proc Natl Acad Sci U S A 1995 ; 92 : 8710-4
92. Kalchman MA, Koide HB, McCutcheon K et al. : HIP1, a human homologue of S. cerevisiae Sla2p, interacts with membrane-associated huntingtin in the brain. Nat Genet 1997 ; 16 : 44-53
93. Wanker EE, Rovira C, Scherzinger E et al. : HIP-I : a huntingtin interacting protein isolated by the yeast two-hybrid system. Hum Mol Genet 1997 ; 6 : 487-95
94. Hoffner G, Kahlem P, Djian P : Perinuclear localization of huntingtin as a consequence of its binding to microtubules through an interaction with beta-tubulin : relevance to Huntington's disease. J Cell Sci 2002 ; 115 : 941-8
95. Modregger J, DiProspero NA, Charles V, Tagle DA, Plomann M : PACSIN 1 interacts with huntingtin and is absent from synaptic varicosities in presymptomatic Huntington's disease brains. Hum Mol Genet 2002 ; 11 : 2547-58
96. Singaraja RR, Hadano S, Metzler M et al. : HIP14, a novel ankyrin domain-containing protein, links huntingtin to intracellular trafficking and endocytosis. Hum Mol Genet 2002 ; 11 : 2815-28
97. Gunawardena S, Her LS, Brusch RG et al. : Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron 2003 ; 40 : 25-40
98. Gunawardena S, Goldstein LS : Cargo-carrying motor vehicles on the neuronal highway : transport pathways and neurodegenerative disease. J Neurobiol 2004 ; 58 : 258-71
99. Li H, Li SH, Johnston H, Shelbourne PF, Li XJ : Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity. Nat Genet 2000 ; 25 : 385-9
100. Szebenyi G, Morfini GA, Babcock A et al. : Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport. Neuron 2003 ; 40 : 41-52
101. Lee WC, Yoshihara M, Littleton JT : Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington's disease. Proc Natl Acad Sci U S A 2004 ; 101 : 3224-9
102. Trushina E, Dyer RB, Badger JD et al. : Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol Cell Biol 2004 ; 24 : 8195-209
103. Li L, Fan M, Icton CD et al. : Role of NR2B-type NMDA receptors in selective neurodegeneration in Huntington disease. Neurobiol Aging 2003 ; 24 : 1113-21
104. Morton AJ, Edwardson JM : Progressive depletion of complexin II in a transgenic mouse model of Huntington's disease. J Neurochem 2001 ; 76 : 166-72
105. Gervais FG, Singaraja R, Xanthoudakis S et al. : Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partner Hippi. Nat Cell Biol 2002 ; 4 : 95-105
106. Dunah AW, Jeong H, Griffin A, Kim YM, Standaert DG, Hersch SM : Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 2002 ; 296 : 2238-43
107. Varani K, Abbracchio MP, Cannella M et al. : Abberant A2A receptor function in peripheral blood cells in Huntington's disease. FASEB J 2003 ; 17 : 2148-50
108. Tarditi A, Camurri A, Varani K et al. : Eraly and transient alteration of A2A receptor signalling in a mouse mode of Huntington's disease. Neurobiol Dis 2006 ; 23 : 44-53
109. Sun Y, Savanenin A, Reddy PH, Liu YF : Polyglutamine-expanded huntingtin promotes sensitization of NMDA receptors via post-synaptic density 95. J Biol Chem 2001 ; 276 : 24713-8
110. Kuhl DE, Phelps ME, Markham CH, Metter EJ, Riege WH, Winter J : Cerebral metabolism and atrophy in Huntington's disease determined by 18FDG and computed tomographic scan. Ann Neurol 1982 ; 12 : 425-34
111. Hayden MR, Martin WR, Stoessl AJ et al. : Positron emission tomography in the early diagnosis of Huntington's disease. Neurology 1986 ; 36 : 888-94
112. Mazziotta JC, Phelps ME, Pahl JJ et al. : Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. N Engl J Med 1987 ; 316 : 357-62
113. Grafton ST, Mazziotta JC, Pahl JJ et al. : A comparison of neurological, metabolic, structural, and genetic evaluations in persons at risk for Huntington's disease. Ann Neurol 1990 ; 28 : 614-21
114. Jenkins BG, Koroshetz WJ, Beal MF, Rosen BR : Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. Neurology 1993 ; 43 : 2689-95
115. Koroshetz WJ, Jenkins BG, Rosen BR, Beal MF : Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann Neurol 1997 ; 41 : 160-5
116. Jenkins BG, Rosas HD, Chen YC et al. : 1H NMR spectroscopy studies of Huntington's disease : correlations with CAG repeat numbers. Neurology 1998 ; 50 : 1357-65
117. Lodi R, Schapira AH, Manners D et al. : Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropa-llidoluysian atrophy. Ann Neurol 2000 ; 48 : 72-6
118. Saft C, Zange J, Andrich J et al. : Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease. Mov Disord 2005 ; 20 : 674-9
119. Gu M, Gash MT, Mann VM, Javoy-Agid F, Cooper JM, Schapira AH : Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol 1996 ; 39 : 385-9
120. Browne SE, Bowling AC, MacGarvey U et al. : Oxidative damage and metabolic dysfunction in Huntington's disease : selective vulnerability of the basal ganglia. Ann Neurol 1997 ; 41 : 646-53
121. Tabrizi SJ, Cleeter MW, Xuereb J, Taanman JW, Cooper JM, Schapira AH : Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann Neurol 1999 ; 45 : 25-32
122. Benchoua A, Trioulier Y, Zala D et al. : Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin. Mol Biol Cell 2006 ; 17 : 1652-63
123. Brouillet E, Jacquard C, Bizat N, Blum D : 3-Nitropropionic acid : a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. J Neurochem 2005 ; 95 : 1521-40
124. Sawa A, Wiegand GW, Cooper J et al. : Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat Med 1999 ; 5 : 1194-8
125. Panov AV, Gutekunst CA, Leavitt BR et al. : Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci 2002 ; 5 : 731-6
126. Choo YS, Johnson GV, MacDonald M, Detloff PJ, Lesort M : Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum Mol Genet 2004 ; 13 : 1407-20
127. Ruan Q, Lesort M, MacDonald ME, Johnson GV : Striatal cells from mutant huntingtin knock-in mice are selectively vulnerable to mitochondrial complex II inhibitor-induced cell death through a non-apoptotic pathway. Hum Mol Genet 2004 ; 13 : 669-81
128. Bae BI, Xu H, Igarashi S et al. : p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron 2005 ; 47 : 29-41
129. Olney JW, Sharpe LG : Brain lesions in an infant rhesus monkey treated with monsodium glutamate. Science 1969 ; 166 : 386-8
130. Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, Martin JB : Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 1986 ; 321 : 168-71
131. Beal MF, Kowall NW, Swartz KJ, Ferrante RJ, Martin JB : Differential sparing of somatostatin-neuropeptide Y and cholinergic neurons following striatal excitotoxin lesions. Synapse 1989 ; 3 : 38-47
132. Beal MF, Ferrante RJ, Swartz KJ, Kowall NW : Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J Neurosci 1991 ; 11 : 1649-59
133. Ferrante RJ, Kowall NW, Cipolloni PB, Storey E, Beal MF : Excitotoxin lesions in primates as a model for Huntington's disease : histopathologic and neurochemical characterization. Exp Neurol 1993 ; 119 : 46-71
134. Brouillet E, Conde F, Beal MF, Hantraye P : Replicating Huntington's disease phenotype in experimental animals. Prog Neurobiol 1999 ; 59 : 427-68
135. Guyot MC, Hantraye P, Dolan R, Palfi S, Maziere M, Brouillet E : Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid. Neuroscience 1997 ; 79 : 45-56
136. Blum D, Gall D, Galas MC, D'Alcantara P, Bantubungi K, Schiffmann SN : The adenosine A1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity. J Neurosci 2002 ; 22 : 9122-33
137. Ikonomidou C, Stefovska V, Turski L : Neuronal death enhanced by N-methyl-D-aspartate antagonists. Proc Natl Acad Sci U S A 2000 ; 97 : 12885-90
138. Beal MF : Role of excitotoxicity in human neurological disease. Curr Opin Neurobiol 1992 ; 2 : 657-62
139. Coyle JT, Puttfarcken P : Oxidative stress, glutamate, and neurodegenerative disorders. Science 1993 ; 262 : 689-95
140. Lipton SA, Rosenberg PA : Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994 ; 330 : 613-22
141. Levine MS, Klapstein GJ, Koppel A et al. : Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J Neurosci Res 1999 ; 58 : 515-32
142. Cepeda C, Ariano MA, Calvert CR et al. : NMDA receptor function in mouse models of Huntington disease. J Neurosci Res 2001 ; 66 : 525-39
143. Laforet GA, Sapp E, Chase K et al. : Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease. J Neurosci 2001 ; 21 : 9112-23
144. Levine MS, Cepeda C, Hickey MA, Fleming SM, Chesselet MF : Genetic mouse models of Huntington's and Parkinson's diseases : illuminating but imperfect. Trends Neurosci 2004 ; 27 : 691-7
145. Zeron MM, Hansson O, Chen N et al. : Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 2002 ; 33 : 849-60
146. Gines S, Ivanova E, Seong IS, Saura CA, MacDonald ME : Enhanced Akt signaling is an early pro-survival response that reflects N-methyl-D-aspartate receptor activation in Huntington's disease knock-in striatal cells. J Biol Chem 2003 ; 278 : 50514-22
147. Shin JY, Fang ZH, Yu ZX, Wang CE, Li SH, Li XJ : Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J Cell Biol 2005 ; 171 : 1001-12
148. Chen N, Luo T, Wellington C, Metzler M, McCutcheon K, Hayden MR, Raymond LA : Subtype-specific enhancement of NMDA receptor currents by mutant huntingtin. J Neurochem 1999 ; 72 : 1890-8
149. Li L, Fan M, Icton CD et al. : Role of NR2B-type NMDA receptors in selective neurodegeneration in Huntington's disease. Neurobiol Aging 2003 ; 24 : 1113-21
150. Guidetti P, Luthi-Carter RE, Augood SJ, Schwarcz R : Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. Neurobiol Dis 2004 ; 17 : 455-61
151. Giorgini F, Guidetti P, Nguyen Q, Bennett SC, Muchowski PJ : A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nat Genet 2005 ; 37 : 526-31
152. Bezprozvanny I, Hayden MR : Deranged neuronal calcium signaling and Huntington disease. Biochem Biophys Res Commun 2004 ; 322 : 1310-7
153. Tang TS, Tu H, Chan EY et al. : Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron 2003 ; 39 : 227-39
154. Gafni J, Ellerby LM : Calpain activation in Huntington's disease. J Neurosci 2002 ; 22 : 4842-9
155. Tang TS, Slow E, Lupu V et al. : Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. Proc Natl Acad Sci U S A 2005 ; 102 : 2602-7
156. Cass WA : Decreases in evoked overflow of dopamine in rat striatum after neurotoxic doses of metamphetamine. J Pharmacol Exp Ther 1997 ; 280 : 105-13
157. Charvin D, Vanhoutte P, Pages C, Borrelli E, Caboche J : Unravelling a role for dopamine in Huntington's disease : the dual role of reactive oxygen species and D2 receptor stimulation. Proc Natl Acad Sci U S A 2005 ; 102 : 12218-23
158. Cyr M, Sotnikova TD, Gainetdinov RR, Caron MG : Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin. FASEB J 2006 ; 20 : 2541-3
159. Maragos WF, Jakel RJ, Pang Z, Geddes JW 6-hydroxydopamine injections into the nigrostriatal pathway attenuate striatal malonate and 3-nitropropionic acid lesions. Exp Neurol 1998 ; 154 : 637-44
160. Reynolds DS, Carter RJ, Morton AJ : Dopamine modulates the susceptibility of striatal neurons to 3-nitropropionic acid in the rat model of Huntington's disease. J Neurosci 1998 ; 18 : 10116-27
161. Blum D, Hourez R, Galas MC, Popoli P, Schiffmann SN : Adenosine receptors and Huntington's disease : implications for pathogenesis and therapeutics. Lancet Neurol 2003 ; 2 : 366-74
162. Blum D, Galas MC, Pintor A et al. : A dual role of adenosine A2A receptors in 3-nitropropionic acid-induced striatal lesions : implications for the neuroprotective potential of A2A antagonists. J Neurosci 2003 ; 23 : 5361-9
163. Popoli P, Pintor A, Domenici MR et al. : Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity : possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. J Neurosci 2002 ; 22 : 1967-75
164. Chou SY, Lee YC, Chen HM et al. : CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model. J Neurochem 2005 ; 93 : 310-20
165. Popoli P Blum D, Martire A, Ledent C, Ceruti S, Abbracchio MP : Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Hutington's disease. Prog Neurobiol 2006 (sous presse)
166. Ryu H, Ferrante RJ : Emerging chemotherapeutic strategies for Huntington's disease. Expert Opin Emerg Drugs 2005 ; 10 : 345-63
167. Dubinsky R, Gray C : CYTE-I-HD : phase I dose finding and tolerability study of systeamine (cystagon) in Hutington's disease. Mov Disord 2006 ; 21 : 530-3
168. Borrell-Pages M, Canals JM, Cordelieres FP et al. : Cystamine and cysteamine increase brain levels of BDNF in Huntington's disease via HSJ1b and transglutaminase. J Clin Invest 2006 ; 116 : 140-24
169. Berger Z, Ravikumar B, Menzies FM et al. : Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet 2006 ; 15 : 433-42
170. Klionsky DJ, Emr SD : Autophagy as a regulated pathway of cellular degradation. Science 2000 ; 290 : 1717-21
171. Ravikumar B, Duden R, Rubinsztein DC : Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum Mol Genet 2002 ; 11 : 1107-17
172. Ravikumar B, Vacher C, Berger Z et al. : Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 2004 ; 36 : 585-95
173. Sarkar S, Floto RA, Berger Z et al. : Lithium induces autophagy by inhibiting inositol monophosphatase. J Cell Biol 2005 ; 170 : 1101-11
174. Sarkar S, Davies JE, Huang Z, Tunnacliffe A, Rubinsztein DC : Trehalose, a novel mTOR- independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J Biol Chem 2007 ; 282 : 5641-52
175. Sarkar S, Perlstein EO, Imarisio S et al. : Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. Nat Chem Biol 2007 ; 3 : 331-8
176. Zhang X, Smith DL, Meriin AB et al. : A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proc Natl Acad Sci U S A 2005 ; 102 : 892-7
177. Heiser V, Engemann S, Brocker W et al. : Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay. Proc Natl Acad Sci U S A 2002 ; 99 : 16400-6
178. Varma H, Voisine C, DeMarco CT et al. : Selective inhibitors of death in mutant huntingtin cells. Nat Chem Biol 2007 ; 2 : 99-100
179. Ferrante RJ, Kubilus JK, Lee J et al. : Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci 2003 ; 23 : 9418-27
180. Hockly E, Richon VM, Woodman B et al. : Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A 2003 ; 100 : 2041-6
181. Gardian G, Browne SE, Choi DK et al. : Neuroprotective Effects of Phenylbutyrate in the N171-82Q Transgenic Mouse Model of Huntington's Disease. J Biol Chem 2005 ; 280 : 556-63
182. Ferrante RJ, Andreassen OA, Dedeoglu A et al. : Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci 2002 ; 22 : 1592-9
183. Huntington Study Group : A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001 ; 57 : 397-404
184. Peschanski M, Bachoud-Levi AC, Hantraye P : Integrating fetal neural transplants into a therapeutic strategy : the example of Huntington's disease. Brain 2004 ; 127 : 1219-28
185. Dunnett SB, Rosser AE : Cell therapy in Huntington's disease. Neurorx 2004 ; 1 : 394-405
186. Peschanski M, Cesaro P, Hantraye P : Rationale for intrastriatal grafting of striatal neuroblasts in patients with Huntington's disease. Neuroscience 1995 ; 68 : 273-85
187. Kendall AL, Rayment FD, Torres EM, Baker HF, Ridley RM, Dunnett SB : Functional integration of striatal allografts in a primate model of Huntington's disease. Nat Med 1998 ; 4 : 727-9
188. Palfi S, Conde F, Riche D et al. : Fetal striatal allografts reverse cognitive deficits in a primate model of Huntington disease. Nat Med 1998 ; 4 : 963-6
189. Fricker-Gates RA, Lundberg C, Dunnett SB : Neural transplantation : restoring complex circuitry in the striatum. Restor Neurol Neurosci 2001 ; 19 : 119-38
190. Isacson O, Brundin P, Kelly PA, Gage FH, Bjorklund A : Functional neuronal replacement by grafted striatal neurones in the ibotenic acid-lesioned rat striatum. Nature 1984 ; 311 : 458-60
191. Dunnett SB, Carter RJ, Watts C et al. : Striatal transplantation in a transgenic mouse model of Huntington's disease. Exp Neurol 1998 ; 154 : 31-40
192. Kendall AL, Rayment FD, Torres EM, Baker HF, Ridley RM, Dunnett SB : Functional integration of striatal allografts in a primate model of Huntington's disease. Nat Med 1998 ; 4 : 727-9
193. Brasted PJ, Watts C, Torres EM, Robbins TW, Dunnett SB : Behavioral recovery after transplantation into a rat model of Huntington's disease : dependence on anatomical connectivity and extensive postoperative training. Behav Neurosci 2000 ; 114 : 431-6
194. Sirinathsinghji DJ, Dunnett SB, Isacson O, Clarke DJ, Kendrick K, Bjorklund A : Striatal grafts in rats with unilateral neostriatal lesions. II. In vivo monitoring of GABA release in globus pallidus and substantia nigra. Neuroscience 1988 ; 24 : 803-11
195. Wictorin K : Anatomy and connectivity of intrastriatal striatal transplants. Prog Neurobiol 1992 ; 38 : 611-39
196. Campbell K, Kalen P, Wictorin K, Lundberg C, Mandel RJ, Bjorklund A : Characterization of GABA release from intrastriatal striatal transplants : dependence on host-derived afferents. Neuroscience 1993 ; 53 : 403-15
197. Nakao N, Ogura M, Nakai K, Itakura T : Embryonic striatal grafts restore neuronal activity of the globus pallidus in a rodent model of Huntington's disease. Neuroscience 1999 ; 88 : 469-77
198. Nakao N, Itakura T : Fetal tissue transplants in animal models of Huntington's disease : the effects on damaged neuronal circuitry and behavioral deficits. Prog Neurobiol 2000 ; 61 : 313-38
199. Hauser RA, Furtado S, Cimino CR et al. : Bilateral human fetal striatal transplantation in Huntington's disease. Neurology 2002 ; 58 : 687-95
200. Kopyov OV, Jacques S, Lieberman A, Duma CM, Eagle KS : Safety of intrastriatal neurotransplantation for Huntington's disease patients. Exp Neurol 1998 ; 149 : 97-108
201. Bachoud-Levi AC, Remy P, Nguyen JP et al. : Motor and cognitive improvements in patients with Huntington's disease after neural transplantation. Lancet 2000 ; 356 : 1975-9
202. Fink JS, Schumacher JM, Ellias SL et al. : Porcine xenografts in Parkinson's disease and Huntington's disease patients : preliminary results. Cell Transplant 2000 ; 9 : 273-8.
203. Rosser AE, Barker RA, Harrower T et al. : Unilateral transplantation of human primary fetal tissue in four patients with Huntington's disease : NEST-UK safety report ISRCTN no 36485475. J Neurol Neurosurg Psychiatry 2002 ; 73 : 678-85
204. Gaura V, Bachoud-Levi AC, Ribeiro MJ et al. : Striatal neural grafting improves cortical metabolism in Huntington's disease patients. Brain 2004 ; 127 : 65-72
205. Kremer B, Clark CM, Almqvist EW et al. : Influence of lamotrigine on progression of early Huntington disease : a randomized clinical trial. Neurology 1999 ; 53 : 1000-11
206. Bachoud-Levi AC, Gaura V, Brugieres P et al. : Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery : a long-term follow-up study. Lancet Neurol 2006 ; 5 : 303-9
207. Alberch J, Perez-Navarro E, Canals JM : Neurotrophic factors in Huntington's disease. Prog Brain Res 2004 ; 146 : 195-229
208. Alexi T, Hughes PE, Roon-Mom WM et al. : The IGF-I amino-terminal tripeptide glycine-proline-glutamate (GPE) is neuroprotective to striatum in the quinolinic acid lesion animal model of Huntington's disease. Exp Neurol 1999 ; 159 : 84-97
209. Perez-Navarro E, Canudas AM, Akerund P, Alberch J, Arenas E : Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4/5 prevent the death of striatal projection neurons in a rodent model of Huntington's disease. J Neurochem 2000 ; 75 : 2190-9
210. Perez Navaro E, Akerud P, Marco S et al. : Neurturin protects striatal projection neurons but not interneurons in a rat model of Huntington's disease. Neuroscience 2000 ; 98 : 89-96
211. Alberch J, Perez-Navarro E, Canals JM : Neuroprotection by neurotrophins and GDNF family members in the excitotoxic model of Huntington's disease. Brain Res Bull 2002 ; 57 : 817-22
212. Anderson KD, Panayotatos N, Corcoran TL, Lindsay RM, Wiegand SJ : Ciliary neurotrophic factor protects striatal output neurons in an animal model of Huntington disease. Proc Natl Acad Sci U S A 1996 ; 93 : 7346-51
213. Mittoux V, Joseph JM, Conde F et al. : Restauration of cognitive and motor functions by ciliary neurotrophic factor in a primate model of Huntington's disease. Hum Gene Ther 2000 ; 11 : 1177-87
214. Almeida LP, Zala D, Aebischer P, Deglon N : Neuroprotective effect of a CNTF-expressing lentiviral vector in the quinolinic acid rat model of Huntington's disease. Neurobiol Dis 2001 ; 8 : 433-46
215. Regulier E, Pereira A, Sommer B, Aebischer P, Deglon N : Dose-dependent neuroprotective effect of ciliary neurotrophic factor delivered via tetracycline-regulated lentiviral vectors in the quinolinic acid rat model of Huntington's disease. Hum Gene Ther 2002 ; 13 : 1981-90
216. Mittoux V, Ouary S, Monville C et al. : Corticostriatopallidal neuroprotection by adenovirus-mediated ciliary neurotrophic factor gene transfer in a rat model of progressive striatal degeneration. J Neurosci 2002 ; 22 : 4478-86
217. Tan SA, Aebischer P : The problems of delivering neuroactive molecules to the CNS. Ciba Found Symp 1996 ; 196 : 211-36
218. Emerich DF, Cain CK, Greco C et al. : Cellular delivery of human CNTF prevents motor and cognitive dysfunction in a rodent model of Huntington's disease. Cell Transplant 1997 ; 6 : 249-66
219. Emerich DF, Winn SR, Hantraye PM et al. : Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease. Nature 1997 ; 386 : 395-9
220. Aebischer P, Schluep M, Deglon N et al. : Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat Med 1996 ; 2 : 696-9
221. Bloch J, Bachoud-Levi AC, Deglon N et al. : Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor : results of a phase I study. Hum Gene Ther 2004 ; 15 : 968-75
222. Beal MF, Ferrante RJ : Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat Rev Neurosci 2004 ; 5 : 373-84